IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Confirmation No.: 4326

HO et al. Art Unit: 1651

Appl. No.: 09/960,244 Examiner: Leon B. Lankford, Jr.
Filed: September 21, 2001 Atty. Docket: 2560.0020000/JAG/D-S

For: Cell Populations Which Co-Express

CD49c and CD90

Supplemental Amendment and Reply Under 37 C.F.R. § 1.111(a)(2)(B)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In further reply to the Office Action mailed October 5, 2007, Applicants' interview with the Examiner on April 3, 2008, and the Examiner's email correspondence of June 11, 2008, Applicants submit herein a claim amendment (new claim 97), as suggested by the Examiner, and discuss why this claim should be allowed.

Amendments to the Claims begin on Page 2.

Remarks begin on Page 4.

Exhibits A through G are attached hereto.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefore (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.